The risk of posterior subcapsular cataracts in granulocyte donors

Burch, John W.; Mair, David; Meny, Geralyn M.; Moroff, Gary; Ching, Steven; Naidoff, Michael A.; Steuer, Eric R; Loftus, Sanaz A.; Armstrong, J.; Clemons, Traci E; Klein, Barbara E. K.

doi:10.1111/j.1537-2995.2005.00594.x

Cited by 25 publications

(32 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The higher risk of the development of posterior subcapsular cataract (PSC) in granulocyte donors was initially reported by Ghodsi and Strauss [33]. Two other studies [34,35] published more recently could not confirm a significant higher incidence of PSC in granulocyte donors compared with platelet donors. In spite of that, both studies revealed a clear association of PSC frequency with the number of granulocyte donations and the cumulative dose of steroids.…”

Section: Discussionmentioning

confidence: 69%

Efficacy and Side Effects of Granulocyte Collection in Healthy Donors

Brockmann

Kramer

Bornhäuser

et al. 2013

Transfus Med Hemother

View full text Add to dashboard Cite

Background: We report on the efficacy and side effects of granulocyte collection, which is comparatively infrequently performed in Germany. Methods: Data from 378 healthy donors who underwent 914 granulocyte collections between 1999 and 2007 were retrospectively analyzed. Donors received G-CSF (lenograstim) at a median dose of 5.58 (3.25-7.36) µg/kg body weight with (n = 243) or without (n = 57) 4 mg dexamethasone. Side effects were recorded by donor monitoring and interview (questionnaire). Results: The median granulocyte yield in apheresis products was 8.47 × 10¹⁰ (3.07-14.92 × 10¹⁰). Granulocyte yields correlated significantly with gender, baseline WBC, PMN and PLT counts, and nicotine consumption. Dexamethasone and lenograstim administration was more effective than lenograstim administration alone (p < 0.001). Side effects of granulocyte mobilization were generally mild: bone pain in 31.4%, headache in 19.6%, and fatigue in 15.7% of donors. During follow-up (4 weeks), pruritus and/or exanthema were reported in 17.6% of donors. Conclusions: Granulocyte mobilization with lenograstim with or without dexamethasone was a safe and effective regimen for granulocyte mobilization. Side effects were tolerable and milder than those seen in peripheral blood stem cell donors. Long-term monitoring of granulocyte donors is important to establish optimal standards for the procedure.

show abstract

Section: Discussionmentioning

confidence: 69%

Efficacy and Side Effects of Granulocyte Collection in Healthy Donors

Brockmann

Kramer

Bornhäuser

et al. 2013

Transfus Med Hemother

View full text Add to dashboard Cite

show abstract

“…There may also be a relationship between iron and platelet activity 33 . Recent studies involving large blood donor databases did not demonstrate an increased of cancer incidence 17 , degenerative brain diseases 34 , ocular disease 35 and diabetes mellitus type 2 36 , whereas an increased risk of upper extremity deep vein thrombosis was reported. Low serum iron levels have been linked with elevated plasma levels of coagulation factor VIII and venous thromboembolic risk 37 .…”

Section: Discussionmentioning

confidence: 97%

Risk of illness, hospitalization and death in a cohort of blood donors in Italy

Gallerani

Volpato

Cellini

et al. 2014

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…2.8.1.2 Corticosteroids It remains controversial whether the administration of corticosteroids along with G-CSF stimulation to granulocyte donors increases the risk of posterior subcapsular cataract [33,34]. However, the administration of corticosteroids to granulocyte donors, especially in frequent donations, should be used with caution.…”

Section: Complications Of Gtx Therapymentioning

confidence: 95%

Guidelines for safety management of granulocyte transfusion in Japan

et al. 2010

View full text Add to dashboard Cite

Granulocyte transfusion (GTX) has recently been revived by the ability to stimulate granulocyte donors with granulocyte colony-stimulating factor (G-CSF), resulting in a greatly increased number of cells that can be collected. However, there is a paucity of guidelines for assessing the appropriateness and safety management of GTX. The objective of this study was to establish guidelines for the safety management of GTX appropriate for the clinical situation in Japan. The Japan Society of Transfusion Medicine and Cell Therapy, Granulocyte Transfusion Task Force issued the first version of guidelines for GTX considering the safety management of both granulocyte donors and patients who receive GTX therapy. The current guidelines cover issues concerning: (1) the appropriateness of medical institutions, (2) management of granulocyte donors, (3) quality assurance of granulocyte concentrates, (4) administration of granulocyte concentrates, (5) evaluation of the effectiveness of GTX therapy, and (6) complications of GTX therapy. The simple 'bag separation method' without apheresis may be recommended for granulocyte collection in pediatric patients. The first version of guidelines for GTX therapy has been established, which may be appropriate for the clinical situation in Japan. Care should be taken to perform the safety management of both granulocyte donors and patients who receive GTX therapy.

show abstract

The risk of posterior subcapsular cataracts in granulocyte donors

Abstract: This study does not support the hypothesis that corticosteroid stimulation of PMN donors is associated with an increased risk of developing a PSC.

Cited by 25 publications

References 17 publications

Efficacy and Side Effects of Granulocyte Collection in Healthy Donors

Efficacy and Side Effects of Granulocyte Collection in Healthy Donors

Risk of illness, hospitalization and death in a cohort of blood donors in Italy

Guidelines for safety management of granulocyte transfusion in Japan

Contact Info

Product

Resources

About